IRIS
PORTA, Camillo Guglielmo Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.801
AS - Asia 3.935
EU - Europa 2.283
SA - Sud America 1.937
AF - Africa 149
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.112
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.632
SG - Singapore 1.670
BR - Brasile 1.631
HK - Hong Kong 819
VN - Vietnam 534
RU - Federazione Russa 434
IT - Italia 429
SE - Svezia 429
CN - Cina 297
GB - Regno Unito 229
ID - Indonesia 205
DE - Germania 198
FR - Francia 191
AR - Argentina 133
CA - Canada 75
AT - Austria 72
FI - Finlandia 65
IN - India 64
EC - Ecuador 60
BD - Bangladesh 56
MX - Messico 52
TR - Turchia 50
CI - Costa d'Avorio 45
JP - Giappone 44
IE - Irlanda 42
ZA - Sudafrica 41
IQ - Iraq 40
NL - Olanda 37
CO - Colombia 33
ES - Italia 31
PK - Pakistan 30
PL - Polonia 27
PY - Paraguay 24
VE - Venezuela 20
MA - Marocco 18
BE - Belgio 15
SA - Arabia Saudita 13
JO - Giordania 12
PE - Perù 12
LT - Lituania 11
UA - Ucraina 11
AZ - Azerbaigian 10
KE - Kenya 10
UY - Uruguay 10
UZ - Uzbekistan 10
CL - Cile 9
EG - Egitto 9
NP - Nepal 9
AE - Emirati Arabi Uniti 8
TN - Tunisia 8
AL - Albania 7
MK - Macedonia 7
BH - Bahrain 6
DO - Repubblica Dominicana 6
GT - Guatemala 5
HN - Honduras 5
JM - Giamaica 5
LB - Libano 5
OM - Oman 5
RS - Serbia 5
AU - Australia 4
BG - Bulgaria 4
BO - Bolivia 4
CH - Svizzera 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
IL - Israele 4
KG - Kirghizistan 4
KR - Corea 4
KZ - Kazakistan 4
LU - Lussemburgo 4
PT - Portogallo 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
BB - Barbados 3
DM - Dominica 3
HU - Ungheria 3
QA - Qatar 3
TH - Thailandia 3
TW - Taiwan 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
DK - Danimarca 2
ET - Etiopia 2
HR - Croazia 2
KH - Cambogia 2
LV - Lettonia 2
MD - Moldavia 2
MY - Malesia 2
MZ - Mozambico 2
NO - Norvegia 2
PH - Filippine 2
PR - Porto Rico 2
RO - Romania 2
SN - Senegal 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
Totale 14.086
Salva come PNG Salva come JPEG
Città #
Hong Kong 804
Singapore 757
Ashburn 687
Fairfield 648
Cambridge 347
Nyköping 338
Woodbridge 265
Houston 254
Seattle 254
Bari 228
Wilmington 225
Chandler 223
Lawrence 220
Roxbury 202
Dallas 201
Jakarta 168
Ho Chi Minh City 165
New York 144
Paris 137
São Paulo 129
Beijing 126
Des Moines 119
Los Angeles 116
Ann Arbor 111
Dong Ket 111
Chicago 96
Hanoi 96
San Diego 85
Inglewood 75
Buffalo 73
Nuremberg 68
London 66
Santa Clara 61
Rio de Janeiro 52
Helsinki 50
Abidjan 45
Dublin 41
Salt Lake City 41
Munich 39
Belo Horizonte 38
Brooklyn 33
Vienna 33
Rome 30
Curitiba 27
Falkenstein 27
Guayaquil 27
Manchester 26
Porto Alegre 25
Salvador 25
Frankfurt am Main 24
Johannesburg 24
Tokyo 24
Montreal 22
Warsaw 22
Milan 21
Brasília 20
Haiphong 20
Toronto 19
Campinas 18
Da Nang 18
Moscow 18
Phoenix 18
Princeton 18
Buenos Aires 17
Guarulhos 17
Boardman 16
Elk Grove Village 16
Quito 16
Istanbul 15
New Bedfont 15
Asunción 14
Chennai 14
Goiânia 14
San Francisco 14
Turku 14
Denver 13
Stockholm 13
Tampa 13
Amman 12
Bogotá 12
Brussels 12
Fortaleza 12
Mexico City 12
Miami 12
Amsterdam 11
Ankara 11
Atlanta 11
Caxias do Sul 11
Dhaka 11
Franca 11
Hounslow 11
Manaus 11
Osasco 11
Sorocaba 11
Bauru 10
Biên Hòa 10
Juiz de Fora 10
Portsmouth 10
Prescot 10
Sterling 10
Totale 8.907
Salva come PNG Salva come JPEG
Nome #
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study 214
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 139
The clonal heterogenicity of circulating tumor cells (CTCs) drives their metastatic potential: a new NOD‐SCID melanoma model 118
KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation 118
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors 110
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 109
Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma—analysis using diagnostic nodes 105
Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey 104
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 103
Integration of lipidomics and transcriptomics reveals reprogramming of the lipid metabolism and composition in clear cell renal cell carcinoma 99
Application of “omics” sciences to the prediction of bone metastases from breast cancer: State of the art 94
Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer 93
Large extracellular vesicles—a new frontier of liquid biopsy in oncology 93
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial 92
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma 92
Exploring the Spectrum of Kidney Ciliopathies 91
Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies 90
An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas 86
The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice 86
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy 85
Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma 85
Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review 84
Massive hyper-progression during anti-PD1 immunotherapy in a young patient with metastatic mucinous adenocarcinoma of the right colon: a case report and literature review 83
Understanding the mechanisms of resistance in EGFR-positive NSCLC: From tissue to liquid biopsy to guide treatment strategy 82
KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer 80
Characterization of the metastatic behavior and gene expression profile (RNAseq) of different melanoma cell lines: a comprehensive in vivo model. 80
Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors 80
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives 80
Hormone signaling pathways as treatment targets in renal cell cancer (Review) 77
Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés 77
An anti-mica/b antibody and il-15 rescue altered nkg2d-dependent nk cell responses in hepatocellular carcinoma 77
1101MO Development of CAR T-cells for future treatment of NETs 77
Acute Kidney Injury in Cancer Patients 75
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial 74
An update on Merkel cell carcinoma 73
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale 73
Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma 73
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis 73
Abstract 2012: In vitro validation of tumor-derived large extracellular vesicles isolation and characterization as suitable tool for liquid biopsy 72
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study 72
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives 71
[Current approaches to the first-line treatment of clear-cell renal cell carcinoma] 71
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 71
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability 71
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications 70
Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial 70
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand? 70
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer 70
Non-Melanoma Skin Cancers: Biological and Clinical Features 70
Primary soft tissue sarcoma of the heart: An emerging chapter in cardio-oncology 69
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 67
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations 66
Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience 66
Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells 66
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma 66
Targeting stim and Orai proteins as an alternative approach in anticancer therapy 66
Opening an onconephrology clinic: Recommendations and basic requirements 66
Abstract 2808: Characterization of the metastatic behavior and gene expression profile (RNAseq) of different melanoma cell lines: a comprehensive in vivo model 65
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 65
Uterine carcinosarcoma: An overview 65
Liquid biopsy in cervical cancer: Hopes and pitfalls 65
Choosing the right cell line for renal cell cancer research 64
Adjuvant therapy in renal cell carcinoma 64
Steroids in prostate cancer: The jury is still out⋯ and even more confused 64
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study 64
Beyond ras and braf: Her2, a new actionable oncotarget in advanced colorectal cancer 64
Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistance 63
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 63
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas 63
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: Final results from an expanded-access trial 63
Prognostic factors and current treatment strategies for renal cell carcinoma metastatic to the brain: An overview 63
A Glimpse in the Future of Malignant Mesothelioma Treatment 63
The role of tivozanib in advanced renal cell carcinoma therapy 62
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 62
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 62
Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases 62
Adamantinoma-like Ewing sarcoma of the salivary glands: a case report and systematic literature review 61
Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer 61
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study 60
How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma 60
Targeted therapy for renal cell carcinoma: Focus on 2nd and 3rd line 59
Renin angiotensin system deregulation as renal cancer risk factor (Review) 59
Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model 59
Playing the devil’s advocate: Should we give a second chance to mTOR inhibition in renal clear cell carcinoma? – ie strategies to revert resistance to mtor inhibitors 59
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis 58
Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer 58
Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis 58
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: Results of the DATECAN project 58
An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy 58
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial 57
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: A systematic review and meta-analysis 57
Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium 57
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 57
Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma 56
Insulin-like growth factor-1 signaling in renal cell carcinoma 56
Prognostic Value of 18 F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel 56
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma 56
Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment 55
Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review 55
Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis 55
Totale 7.425
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.694
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.694
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.398 0 0 0 0 0 11 252 542 78 288 60 167
2021/20221.514 273 22 10 16 66 162 24 40 150 148 226 377
2022/20231.206 236 152 137 22 73 139 138 77 151 10 20 51
2023/2024716 46 240 48 40 54 110 22 39 38 11 13 55
2024/20254.713 207 27 493 256 83 331 473 235 259 370 730 1.249
2025/20264.924 1.294 467 832 1.438 815 78 0 0 0 0 0 0
Totale 15.666